Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG Fluorescence Imaging in Hepatocellular Carcinoma
NCT03793322Phase 1Unknown
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in hepatocellular carcinoma (HCC), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoints: The accuracy of detecting small liver tumor by ICG fluorescence at 3 Days and The accuracy of positive margins of resection detected by ICG fluorescence at 3 Days. Status: unknown.
02
Drugs
indocyanine green
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03793322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793322.